Drug intelligence / Profile preview

Fevicid

Development stage
Unknown
Lead developer
Greenlife
Modality
Small Molecules
Administration
Topical
01

Overview

**Fevicid** is a topical fixed-dose dermatological cream containing clobetasol propionate 0.05% w/w, a highly potent corticosteroid, and clotrimazole 1% w/w, an imidazole antifungal. Clobetasol activates glucocorticoid receptors to suppress inflammatory signaling, while clotrimazole inhibits fungal ergosterol biosynthesis through inhibition of sterol 14-alpha-demethylase. The product was registered in Nigeria for local treatment of inflammatory and fungal skin conditions, including eczema, psoriasis, contact dermatitis, ringworm, athlete's foot, and jock itch. The Nigerian regulatory listing identifies Greenlife Pharmaceuticals as applicant and Kremoint Pharma as manufacturer; its registration was listed as inactive after an expiry date of May 27, 2026. ([greenbook.nafdac.gov.ng](https://greenbook.nafdac.gov.ng/products/details/533))

Brand names
Fevicid
Other names
Fevicid Cream
02

Targets

CYP51A1 (Sterol 14α-demethylase)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on Fevicid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fevicid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call